GDF/BMP Antagonist Compositions Targeting Pulmonary Vascular Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for pulmonary hypertension do not provide a cure and fail to directly address vascular remodeling and muscularization of blood vessels, highlighting a significant unmet need for effective treatments.
Innovation Solution
The use of GDF/BMP antagonists, such as soluble ActRIIA polypeptides and ALK4:ActRIIB heterodimers, to reduce blood pressure, cardiac hypertrophy, and vascular remodeling in pulmonary arterial hypertension models, offering a mechanism beyond traditional ActRII signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If traditional pulmonary hypertension therapies (phosphodiesterase-5 inhibitors, prostacyclins, endothelin receptor antagonists) are used, then blood pressure reduction is achieved, but vascular remodeling and muscularization of blood vessels are not directly treated
Solution Approach 1:
The patent uses GDF/BMP antagonists as intermediary substances that block the signaling pathways involved in vascular remodeling. These antagonists act as mediators between the pathological processes and the therapeutic effect, preventing the formation of new muscle cells and remodeling of blood vessels while also reducing pulmonary blood pressure.
Solution Approach 2:
The patent changes the therapeutic parameter from单纯 blood pressure reduction to include inhibition of vascular remodeling processes. By introducing GDF/BMP antagonists that target specific signaling pathways (BMP, GDF, TGF-beta), the treatment mechanism is expanded to address multiple pathological parameters simultaneously, including cellular proliferation, extracellular matrix deposition, and vascular smooth muscle differentiation.
2Reliability
If GDF/BMP antagonists are used to treat vascular remodeling, then direct treatment of underlying pathology is achieved, but the mechanism goes beyond traditional ActRII signaling pathways
Solution Approach 1:
The patent employs GDF/BMP antagonists that possess multi-functionality by targeting multiple signaling pathways (BMP, GDF, TGF-beta) through a single therapeutic agent. These antagonists can bind to multiple receptors and inhibit multiple downstream pathways, providing a universal treatment approach that addresses various aspects of vascular remodeling through one mechanism.
Solution Approach 2:
The patent utilizes composite therapeutic mechanisms that combine multiple signaling pathway inhibitions. The GDF/BMP antagonists function as composite agents that simultaneously interfere with multiple biological pathways, creating a synergistic effect that enhances the treatment of vascular remodeling while managing the complexity of target pathways.
3Ease of operation
If current pulmonary hypertension therapies are administered, then symptomatic relief is provided, but exercise capacity and long-term outcomes remain limited
Solution Approach 1:
The patent applies preliminary action by using GDF/BMP antagonists to prevent vascular remodeling before it severely impacts exercise capacity. By blocking the pathological processes early in the disease progression, the treatment preserves vascular function and maintains better exercise capacity and functional outcomes before significant damage occurs.
Solution Approach 2:
The patent employs preliminary anti-action by using GDF/BMP antagonists to counteract the pathological remodeling processes before they lead to irreversible damage. The antagonists preemptively block the signaling pathways that would otherwise promote vascular smooth muscle proliferation and extracellular matrix deposition, thereby preserving exercise capacity and functional status.
Data Source
AI summary
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.